Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22830105 | 0.98 | LMNA (0.31) | LMNAMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22830126 | 0.87 | LMNA (0.35) | LMNAMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22830054 | 0.87 | LMNA (0.35) | LMNAMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22830091 | 0.87 | LMNA (0.35) | LMNAMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL29934233 | 0.86 | LMNA (0.40) | LMNAMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22830211 | 0.85 | LMNA (0.36) | LMNAMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22830271 | 0.84 | KMT2A (0.39) | LMNAMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL27194581 | 0.83 | KMT2A (0.38) | LMNAMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22830171 | 0.82 | KIF11 (0.35) | LMNAMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22855324 | 0.80 | LMNA (0.40) | LMNAMAPTCYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | G6PC1, GAA, GBA3 | LMNA 241/4885MAPT 863/4885CYP3A4 4459/4885 |
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | G6PC1, GAA, GBA3 | LMNA 144/4885MAPT 892/4885CYP3A4 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.